Patents Issued in January 12, 2021
  • Patent number: 10888560
    Abstract: The invention provides compositions and methods for the induction of cell death, for example, cancer cell death. Combinations of compounds and related methods of use are disclosed, including the use of compounds in therapy for the treatment of cancer and selective induction of apoptosis in cells. The disclosed drug combinations can have lower neurotoxicity effects than other compounds and combinations of compounds.
    Type: Grant
    Filed: October 1, 2018
    Date of Patent: January 12, 2021
    Assignees: The Board of Trustees of the University of Illinois, Vanquish Oncology, Inc.
    Inventors: Paul J. Hergenrother, Rachel C. Botham, Timothy M. Fan, Mark J. Gilbert, Michael K. Handley, Howard S. Roth, Theodore M. Tarasow
  • Patent number: 10888561
    Abstract: The disclosures herein relate to novel compounds of formula wherein R1, R2, R3 and R4 are as defined herein, and their use in treating, preventing, ameliorating, controlling or reducing cerebrovascular or vascular disorders associated with CGRP receptor function.
    Type: Grant
    Filed: April 8, 2019
    Date of Patent: January 12, 2021
    Assignee: Heptares Therapeutics Limited
    Inventors: John Andrew Christopher, Miles Stuart Congreve, Sarah Joanne Bucknell, Francesca Deflorian, Mark Pickworth, Jonathan Stephen Mason
  • Patent number: 10888562
    Abstract: Tartrate salts of the compound of structure (I), crystalline forms thereof, and therapeutic applications thereof for treating solid tumors (e.g., advanced solid tumor) or hematopoietic cancers. Also provided herein are methods for synthesizing the tartrate salts and the crystalline forms thereof.
    Type: Grant
    Filed: April 5, 2019
    Date of Patent: January 12, 2021
    Assignee: Sumitomo Dainippon Pharma Oncology, Inc.
    Inventors: Adam Siddiqui-Jain, Paul Flynn, Akihito Nonoyama, Akihito Kiguchiya
  • Patent number: 10888563
    Abstract: The invention provides fused heterocyclic organic compounds such as dihydropyrazolopyridotriazinones, compositions containing such compounds, medical kits, and methods for using such compounds and compositions for body contouring and/or reduction of fat in a subject.
    Type: Grant
    Filed: July 30, 2018
    Date of Patent: January 12, 2021
    Assignee: Alevere Medical Corporation
    Inventor: Tim Kamerzell
  • Patent number: 10888564
    Abstract: The disclosure generally relates to compounds of formulas (I) and (II)7 including compositions and methods for treating human immunodeficiency virus (HIV) infection. The disclosure provides novel inhibitors of HIV-1 integrase, pharmaceutical compositions containing such compounds, and methods for using these compounds in the treatment of HIV infection.
    Type: Grant
    Filed: January 26, 2018
    Date of Patent: January 12, 2021
    Assignee: Institute for Cancer Research
    Inventors: Mark D. Andrake, Anna Marie Skalka, George W. Merkel
  • Patent number: 10888565
    Abstract: The disclosure relates to compounds and compositions for forming bone and methods related thereto. In one embodiment, the disclosure relates to a composition comprising a compound disclosed herein, such as 2,4-diamino-1,3,5-triazine derivatives or salts thereof, for use in bone growth processes. In a typical embodiment, a bone graft composition is implanted in a subject at a site of desired bone growth or enhancement.
    Type: Grant
    Filed: January 2, 2020
    Date of Patent: January 12, 2021
    Assignees: Emory University, The United States Government as represented by the Department of Veterans Affairs
    Inventors: Scott D. Boden, Sreedhara Sangadala
  • Patent number: 10888566
    Abstract: Compounds for the chemosensitization of antibiotic resistant bacteria such as multidrug resistant (MDR) Pseudomonas aeruginosa (Pa) are provided. The compounds inhibit the MDR efflux proteins and re-sensitize the bacteria towards killing by antibiotics. Thus, the compounds are used in combination with antibiotics to treat or prevent infections caused by MDR bacteria.
    Type: Grant
    Filed: October 7, 2020
    Date of Patent: January 12, 2021
    Assignee: KING ABDULAZIZ UNIVERSITY
    Inventors: Moustafa E. El-Araby, Abdelsattar M. Omar, Mahmoud A. Elfaky, Maan T. Khayat, Ghufran A. Alhowswi, Fatma M. Alhaity, Muna M. Albeeshy
  • Patent number: 10888567
    Abstract: Pharmaceutical compositions comprising 3-aminoisoxazolopyridine compounds of the Formula I having IDO1 and/or TDO inhibitory activity are described, where W is CR1, N or N-oxide; X is CR2, N or N-oxide; Y is CR3, N or N-oxide; Z is CR4, N or N-oxide; and at least one of W, X, Y, and Z is N or N-oxide; and R9 and R10 are as defined. Also described are methods of using such compounds in the treatment of various conditions, such as cancer.
    Type: Grant
    Filed: August 12, 2015
    Date of Patent: January 12, 2021
    Assignee: Auckland UniServices Limited
    Inventors: Brian Desmond Palmer, Lai Ming Ching, Swarnalatha Akuratiya Gamage
  • Patent number: 10888568
    Abstract: The present invention relates to use of antipsychotic phenothiazine derivative for treatment of cancer. The invention also provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating a cancer, and/or preventing or delaying cancer recurrence based on trifluoperazine. The invention further provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating cancer based on thioridazine and its enantiomers. Additionally, the invention provides a use for manufacture a medicament, a pharmaceutical composition and a method for treating KRAS mutant NSCLC comprising thioridazine.
    Type: Grant
    Filed: October 29, 2018
    Date of Patent: January 12, 2021
    Assignee: National Yang Ming University
    Inventors: Chi-Ying Huang, Jane Hsiao, Pan-Chyr Yang, Meng-Hua Lee
  • Patent number: 10888569
    Abstract: The disclosure relates to improved therapeutic methods for treating cancer patients. The methods include a method for treating cancer in a subject comprising administering an effective amount of a BACH1 inhibitor and an ETC inhibitor to the subject. Further aspects of the disclosure relate to a method for treating cancer in a subject comprising: administering a first therapeutic regimen comprising an ETC inhibitor to the subject after a biological sample from the subject was determined to have a decreased or substantially the same level of expression of BACH1 relative to a control sample or to a cut-off value; wherein the first therapeutic regimen excludes a BACH1 inhibitor; or administering a second therapeutic regimen comprising a BACH1 inhibitor and an ETC inhibitor to the subject after a biological sample from the subject was determined to have an increased level of expression of BACH1 relative to a control sample or a cut-off value.
    Type: Grant
    Filed: June 11, 2018
    Date of Patent: January 12, 2021
    Assignee: The University of Chicago
    Inventors: Marsha Rosner, Jiyoung Lee
  • Patent number: 10888570
    Abstract: Disclosed herein is a stable, ready-to-use liquid formulation comprising spironolactone and its method of use.
    Type: Grant
    Filed: May 19, 2020
    Date of Patent: January 12, 2021
    Assignee: CMP DEVELOPMENT LLC
    Inventors: Anthony Pipho, Michael Paul DeHart
  • Patent number: 10888571
    Abstract: A method and composition for preserving muscle mass and function by increasing muscle protein synthesis and/or decreasing muscle protein degradation in mammals is disclosed. In one embodiment, the mammals are administered a protein building composition comprising at least two of an essential amino acid, an amino acid derivative, and a nitrogenous organic acid. In a particular embodiment, the protein building composition comprises leucine, L-carnitine, and creatine. The protein building composition can decrease TNF-? and increase mTOR expression in muscle.
    Type: Grant
    Filed: December 16, 2016
    Date of Patent: January 12, 2021
    Assignee: Lonza Consumer Health Inc.
    Inventors: Aouatef Bellamine, Ilya Zhivkovich, Ulla Freitas
  • Patent number: 10888572
    Abstract: A hydrated lecithin carrier vesicle composition includes lecithin and a triglyceride source or fatty acid in conditioned water. The disclosed compositions may be used for controlling appetite, weight loss, modulating effects from alcohol consumption, and/or delivering active agents to the small intestine.
    Type: Grant
    Filed: December 2, 2016
    Date of Patent: January 12, 2021
    Assignee: BIO-UP MIMETIC TECHNOLOGIES, INC.
    Inventors: Donald F. Hodgson, Crispin G. S. Eley
  • Patent number: 10888573
    Abstract: Phospholipid preparations effective in improving brain development and brain rehabilitation are provided herein.
    Type: Grant
    Filed: March 9, 2017
    Date of Patent: January 12, 2021
    Assignee: ENZYMOTEC LTD.
    Inventors: Asher Widberg, Hala Laoz, Gai Ben-Dror, Yifat Berkov, Yael Lifshitz, Yael Herzog
  • Patent number: 10888574
    Abstract: The present disclosure relates to a method for suppressing obesity, which includes administering to a subject a compound represented by the following formula wherein n is an integer of 1 to 5; when n is 1, R1 is —OH or —O-glycosyl; when n is an integer of 2 to 5, one R1 is —OH and the other R1(s) is/are —O-glycosyl; and R2 is -glycosyl.
    Type: Grant
    Filed: September 28, 2018
    Date of Patent: January 12, 2021
    Assignee: KINJIRUSHI CO.. LTD.
    Inventors: Isao Okunishi, Tomoe Kato
  • Patent number: 10888575
    Abstract: The invention provides a combination comprising zidovudine or a pharmaceutically acceptable derivative thereof and a carbapenem or a pharmaceutically acceptable derivative thereof, optionally with a polymyxin selected from polymyxin E and polymyxin or a pharmaceutically acceptable derivative thereof. This combination is particularly useful for the treatment of microbial infections.
    Type: Grant
    Filed: July 11, 2017
    Date of Patent: January 12, 2021
    Inventors: Anthony Coates, Yanmin Hu
  • Patent number: 10888576
    Abstract: The present invention provides a composition comprising HMB and ATP. Methods of administering HMB and ATP to an animal are also described. HMB and ATP are administered to increase power and strength. The combination of HMB and ATP together has a synergistic effect, which results in a surprising and unexpected level of improvement in power and strength. HMB and ATP are also administered to increase lean body mass and muscle hypertrophy and to prevent typical declines in performance that are characteristic of overreaching.
    Type: Grant
    Filed: October 8, 2018
    Date of Patent: January 12, 2021
    Assignee: Metabolic Technologies, Inc.
    Inventors: Shawn Baier, Larry Kolb, John Rathmacher
  • Patent number: 10888577
    Abstract: There is disclosed herein methods, uses and systems for the detection, diagnosis, prognosis, treatment or prevention of a disease or condition comprising cartilage degeneration in a subject that is in need thereof. The methods comprise the use, inhibition or measurement of at least one of miR-181 a-5p and miR-4454, in the subject.
    Type: Grant
    Filed: January 31, 2017
    Date of Patent: January 12, 2021
    Assignee: UNIVERSITY HEALTH NETWORK
    Inventors: Mohit Kapoor, Akihiro Nakamura, Raja Rampersaud
  • Patent number: 10888578
    Abstract: Antisense oligomer conjugates complementary to a selected target site in the human dystrophin gene to induce exon 51 skipping are described.
    Type: Grant
    Filed: December 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Sarepta Therapeutics, Inc.
    Inventors: Marco A. Passini, Gunnar J. Hanson
  • Patent number: 10888579
    Abstract: Compositions and methods for reducing susceptibility to infectious disease in bees using RNA interference technology, and more particularly, prevention and treatment of viral infections in honeybees such as Israel acute paralysis virus (IAPV) by feeding of pathogen-specific dsRNA. Further, multiple-pathogen specific dsRNA is disclosed.
    Type: Grant
    Filed: July 1, 2013
    Date of Patent: January 12, 2021
    Assignee: BEEOLOGICS INC.
    Inventors: Nitzan Paldi, Gal Yarden
  • Patent number: 10888580
    Abstract: The present invention provides methods for alleviating pain and discomfort associated with a dry eye condition; methods for alleviating pain and discomfort while minimizing at least one skin imperfection; and methods for alleviating pain and discomfort while facilitating wound healing. The methods involve administering to a subject in need thereof a composition comprising hyaluronan with high elasticity.
    Type: Grant
    Filed: July 2, 2019
    Date of Patent: January 12, 2021
    Assignee: Matrix Biology Institute
    Inventors: Carlos Belmonte, Janet L. Denlinger
  • Patent number: 10888581
    Abstract: The present disclosure provides a heterodimeric, conditionally active chimeric antigen receptor (CAR), and a nucleic acid comprising a nucleotide sequence encoding the CAR. The present disclosure provides cells genetically modified to produce the CAR. A CAR of the present disclosure can be used in various methods, which are also provided.
    Type: Grant
    Filed: December 7, 2017
    Date of Patent: January 12, 2021
    Assignee: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
    Inventors: Chia-Yung Wu, James Onuffer, Wendell A. Lim
  • Patent number: 10888582
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 10, 2020
    Date of Patent: January 12, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
  • Patent number: 10888583
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: March 27, 2020
    Date of Patent: January 12, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
  • Patent number: 10888584
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: January 12, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
  • Patent number: 10888585
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: January 12, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
  • Patent number: 10888586
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 12, 2020
    Date of Patent: January 12, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Franziska Hoffgaard, Jens Fritsche, Oliver Schoor, Toni Weinschenk, Daniel Johannes Kowalewski, Chih-Chiang Tsou
  • Patent number: 10888587
    Abstract: The present invention relates to peptides, proteins, nucleic acids and cells for use in immunotherapeutic methods. In particular, the present invention relates to the immunotherapy of cancer. The present invention furthermore relates to tumor-associated T-cell peptide epitopes, alone or in combination with other tumor-associated peptides that can for example serve as active pharmaceutical ingredients of vaccine compositions that stimulate anti-tumor immune responses, or to stimulate T cells ex vivo and transfer into patients. Peptides bound to molecules of the major histocompatibility complex (MHC), or peptides as such, can also be targets of antibodies, soluble T-cell receptors, and other binding molecules.
    Type: Grant
    Filed: June 18, 2020
    Date of Patent: January 12, 2021
    Assignee: IMMATICS BIOTECHNOLOGIES GMBH
    Inventors: Heiko Schuster, Janet Peper, Philipp Wagner, Hans-Georg Rammensee
  • Patent number: 10888588
    Abstract: Disclosed is a fully chemically defined, small molecule-mediated, directed differentiation system that promotes differentiation of stem cells, including embryonic stem cells, induced pluripotent stem cells, and adult stem cells, such as human forms of these stem cell types, to ventricular cardiomyocytes in a highly efficient, reproducible and scalable fashion. Also disclosed is a cost-effective and efficient protocol, or method, for generating cardiomyocytes and a cost-effective and efficient method of maturing cardiomyocytes. The disclosed differentiation system provides a platform to perform large-scale pharmacological screenings and to provide a valuable source of each of cardiac progenitor cells and cardiomyocytes for cell replacement therapies in cardiac repair.
    Type: Grant
    Filed: October 17, 2014
    Date of Patent: January 12, 2021
    Assignees: ICAHN SCHOOL OF MEDICINE AT MOUNT SINAI, THE UNIVERSITY OF HONG KONG
    Inventors: Roger Joseph Hajjar, Camie W. Chan
  • Patent number: 10888589
    Abstract: Methods and compositions for modifying stem cells using one or more ZFPs are disclosed. Such methods and compositions are useful for facilitating processes such as, for example, dedifferentiating cells, differentiating stem cells into the desired phenotype, propagating stem cells and/or facilitating cloning.
    Type: Grant
    Filed: April 13, 2017
    Date of Patent: January 12, 2021
    Assignee: Sangamo Therapeutics, Inc.
    Inventors: Alan P. Wolffe, Michael Moore, Timothy Farries, Trevor Collingwood, Fyodor Urnov
  • Patent number: 10888590
    Abstract: The present invention is directed to a medicated oil composition comprising propolis, about 1-40% by weight, a carrier, about 30-90% by weight, an analgesic, about 0.1-10% by weight, a surfactant, about 0.25-20% by weight, and a diluent, about 5-50% by weight.
    Type: Grant
    Filed: July 23, 2018
    Date of Patent: January 12, 2021
    Assignee: MatrixMed Inc.
    Inventors: Randal Alexander Serafini, Shiv Krishnan, Jonathan Patrick Masterson, IV
  • Patent number: 10888591
    Abstract: Provided are vesicles derived from bacteria belonging to the genus Micrococcus, a composition and a use thereof, wherein the vesicles and the composition comprising the same may be effectively used for the development of a method of diagnosing gastric cancer, pancreatic cancer, cholangiocarcinoma, breast cancer, ovarian cancer, bladder cancer, myocardial infarction, cardiomyopathy, atrial fibrillation, variant angina, chronic obstructive pulmonary disease (COPD), dementia, or diabetes.
    Type: Grant
    Filed: September 6, 2019
    Date of Patent: January 12, 2021
    Assignee: MD HEALTHCARE INC.
    Inventor: Yoon-Keun Kim
  • Patent number: 10888592
    Abstract: The present invention relates to pharmaceutical and food compositions for inducing satiation and prolonging satiety in subjects in need thereof. In particular, the present invention relates to a method of inducing satiation in a subject in need thereof comprising administering to the subject an effective amount of Hafnia alvei.
    Type: Grant
    Filed: April 5, 2017
    Date of Patent: January 12, 2021
    Assignees: TARGEDYS, INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM)
    Inventors: Serguei Fetissov, Pierre Dechelotte, Jonathan Breton, Gregory Lambert, Romain Legrand, Nicolas Lucas
  • Patent number: 10888593
    Abstract: Disclosed are compositions and methods that include or utilize plant growth promoting rhizobacteria (PGPR) for improving growth and health in plants and animals. The compositions and methods include or utilize a plant growth promoting rhizobacteria (PGPR) that expresses a protein associated with pectin metabolism, and a saccharide comprising pectin or a pectin-related saccharide.
    Type: Grant
    Filed: March 30, 2017
    Date of Patent: January 12, 2021
    Assignee: AUBURN UNIVERSITY
    Inventors: Mark R. Liles, Joseph Kloepper
  • Patent number: 10888594
    Abstract: The present invention provides a genetically recombinant vaccinia virus effective in preventing or treating cancer. Specifically, the present invention provides a vaccinia virus comprising two polynucleotides, a polynucleotide encoding IL-7 and a polynucleotide encoding IL-12; a combination kit of two vaccinia viruses, a vaccinia virus comprising a polynucleotide encoding IL-7 and a vaccinia virus comprising a polynucleotide encoding IL-12; and use of the two vaccinia viruses in combination.
    Type: Grant
    Filed: July 31, 2017
    Date of Patent: January 12, 2021
    Assignees: National University Corporation Tottori University, Astellas Pharma Inc.
    Inventors: Shinsuke Nakao, Tatsuya Kawase, Takafumi Nakamura
  • Patent number: 10888595
    Abstract: In a system and process for selectively purifying various pharmacologically-relevant components of a source plant such as cannabis, an initial step provides a low-temperature, robust essential oil/terpene capture that also dehydrates and decarboxylates the starting product—fresh raw cannabis—by means of a vacuum-assisted microwave distillation process. By doing the terpene capture under vacuum distillation temperature may be kept low. The low distillation temperature maximizes yields of thermally-sensitive components such as terpenes and cannabinoids. The system includes an oil/water separator configured to prevent leakage of ambient air into the system.
    Type: Grant
    Filed: August 4, 2017
    Date of Patent: January 12, 2021
    Inventor: Jose Rivas
  • Patent number: 10888596
    Abstract: The invention relates to a method of preparing cannabis extracts, including shatter, budder and wax extracts. The extraction method can provide a high quality and pure extraction product of THC from cannabis plant material, as either a shatter, wax or budder end extraction product. The extracted product is free of polar cannabis plant material, chlorophyll and residual solvents, has a high concentrate of THC, and can be used for dabbing, vaping or smoking consumption by a user. Suitable solvents for the method are gases selected from the group consisting of propane, butane or iso-butane, and the preferred solvent is propane. A key step of the method of the present invention is recovering solvent under atmospheric vacuum and, therefore, obtaining an extraction product that is purified of solvent and has no solvent.
    Type: Grant
    Filed: December 28, 2018
    Date of Patent: January 12, 2021
    Assignee: Cold Baked LLC
    Inventor: Joshua Hindi
  • Patent number: 10888597
    Abstract: The present invention provides a method for treating brain stroke, including: administering to a subject in need a composition, including: an extract of a mixture, wherein the mixture includes Chuanxiong Rhizoma, Rhei Radix et Rhizoma, Angelicae Dahuricae Radix, Scutellaria baicalensis, Coptidis Rhizoma, Gardeniae Fructus, and Carica papaya.
    Type: Grant
    Filed: July 23, 2019
    Date of Patent: January 12, 2021
    Assignee: ENLIVEN BIOTECHNOLOGY CO, LTD.
    Inventors: Jaan-Yih Tsai, Lin-Yu Tsai, Yih-Chih Tsai
  • Patent number: 10888598
    Abstract: Provided herein are low salt ophthalmic pharmaceutical composition and methods of use thereof, for example, in the treatment of dry eye syndrome.
    Type: Grant
    Filed: January 23, 2018
    Date of Patent: January 12, 2021
    Assignee: ALLERGAN, INC.
    Inventors: Peter A. Simmons, Joseph G. Vehige
  • Patent number: 10888599
    Abstract: The invention relates to various compositions for improving exercise performance and/or recovery. The invention also relates to methods of using these compositions and kits including these compositions to improve exercise performance and/or recovery.
    Type: Grant
    Filed: June 13, 2016
    Date of Patent: January 12, 2021
    Assignee: Beachbody, LLC
    Inventors: Nima Alamdari, Michael Wilson, May Lam
  • Patent number: 10888600
    Abstract: The present disclosure provides compositions and methods useful for treating or preventing diseases or disorders where beta amyloid accumulation or aggregation contributes to the pathology or symptomology of the disease, for example Alzheimer's disease.
    Type: Grant
    Filed: February 27, 2018
    Date of Patent: January 12, 2021
    Assignee: THE GENERAL HOSPITAL CORPORATION
    Inventors: Rudolph Emile Tanzi, Ana Griciuc
  • Patent number: 10888601
    Abstract: The present invention provides methods for treating angiogenic eye disorders by sequentially administering multiple doses of a VEGF antagonist to a patient. The methods of the present invention include the administration of multiple doses of a VEGF antagonist to a patient at a frequency of once every 8 or more weeks. The methods of the present invention are useful for the treatment of angiogenic eye disorders such as age related macular degeneration, diabetic retinopathy, diabetic macular edema, central retinal vein occlusion, branch retinal vein occlusion, and corneal neovascularization.
    Type: Grant
    Filed: April 29, 2019
    Date of Patent: January 12, 2021
    Assignee: REGENERON PHARMACEUTICALS, INC.
    Inventor: George D. Yancopoulos
  • Patent number: 10888602
    Abstract: The disclosure provides, among other things, compositions that bind to and inhibit the biological activity of soluble biomolecules, as well as pharmaceutical compositions thereof. Also provided herein are a number of applications (e.g., therapeutic applications) in which the compositions are useful.
    Type: Grant
    Filed: August 7, 2019
    Date of Patent: January 12, 2021
    Assignee: NaNotics, LLC
    Inventor: Louis Hawthorne
  • Patent number: 10888603
    Abstract: The present invention provides a method of treating cancer with a combination of IL-2 (e.g., extended-PK IL-2), an integrin-binding-Fc fusion protein, and a cancer vaccine. The methods of the invention can be used to treat a broad range of cancer types.
    Type: Grant
    Filed: February 10, 2017
    Date of Patent: January 12, 2021
    Assignees: The Board of Trustees of the Leland Stanford Junior University, Massachusetts Institute of Technology
    Inventors: Karl Dane Wittrup, Darrell J. Irvine, Cary Francis Opel, Kelly Dare Moynihan, Jennifer R. Cochran, Byron Hua Kwan
  • Patent number: 10888604
    Abstract: The present invention relates to polypeptides and analogues thereof for use in the treatment of diabetes and bone disorders. Also disclosed are pharmaceutical compositions comprising the polypeptides and analogues thereof, and methods for the treatment of diabetes and bone disorders.
    Type: Grant
    Filed: December 5, 2016
    Date of Patent: January 12, 2021
    Inventors: Victor Gault, Nigel Irwin
  • Patent number: 10888605
    Abstract: The present invention relates to pharmaceutical compositions of the GLP-1 peptide semaglutide comprising no more than 0.01% (w/w) phenol, their preparation, kits comprising such compositions as well as uses thereof.
    Type: Grant
    Filed: January 28, 2020
    Date of Patent: January 12, 2021
    Assignee: Novo Nordisk A/S
    Inventors: Eva Horn Moeller, Michael Duelund Soerensen, Joakim Lundqvist
  • Patent number: 10888606
    Abstract: A peptide with anti-inflammatory activity is described, wherein the peptide comprises at least one amino acid sequence among SEQ ID NO: 2 to SEQ ID NO: 179, the peptide has above 80% homology of amino acid sequence with above-mentioned sequences, or the peptide is the fragment of the above-mentioned peptides. The peptides that have at least one amino acid sequence of SEQ ID NO: 2 to SEQ ID NO: 179 shows outstanding efficacy in both suppressing inflammation and in prophylactic means. Therefore, the composition comprising those peptides can be used as anti-inflammatory pharmaceutical compositions or as cosmetic compositions, in turn, treating and preventing a variety of different types of inflammatory diseases.
    Type: Grant
    Filed: December 21, 2018
    Date of Patent: January 12, 2021
    Assignee: GEMVAX & KAEL CO., LTD.
    Inventors: Sang Jae Kim, Kyung Hee Kim, Kyu-Yong Lee, Seong-Ho Koh, Hyun-Hee Park, Sung Jin Huh, Woo Jin Lee, Bum Joon Kim
  • Patent number: 10888607
    Abstract: The present disclosure provides methods of screening, diagnosing, monitoring and/or treating acid sphingomyelinase (ASM) disorders such as Niemann-Pick disease. In particular, the methods encompass techniques for improved diagnosis and/or treatment of an ASM disorder, for example using enzyme replacement therapy.
    Type: Grant
    Filed: June 8, 2018
    Date of Patent: January 12, 2021
    Assignee: Genzyme Corporation
    Inventors: Wei-Lien Chuang, Gerald F. Cox, X. Kate Zhang
  • Patent number: 10888608
    Abstract: The technology relates generally to the field of immunology and relates in part to methods for activating T cells and other cells resulting in an immune response against a target antigen. The technology also relates to costimulation of therapeutic cells that express chimeric antigen receptors that recognize target antigens using chimeric MyD88- and CD40-derived polypeptides. The technology further relates in part to therapeutic cells that express chimeric antigen receptors, wherein the chimeric antigen receptors have an endodomain that includes MyD88- and CD40-derived polypeptides, and methods for treating patients using the modified therapeutic cells.
    Type: Grant
    Filed: September 1, 2015
    Date of Patent: January 12, 2021
    Assignee: Bellicum Pharmaceuticals, Inc.
    Inventors: David Spencer, Aaron Edward Foster, Kevin Slawin
  • Patent number: 10888609
    Abstract: The present invention provides in certain embodiments compositions comprising at least one CD200 inhibitor, and methods of reversing or modulating immune suppression in a patient having a disease or disorder arising from abnormal cell growth, function or behavior, which method comprises administering to a patient in need thereof a CD200 inhibitor composition.
    Type: Grant
    Filed: November 2, 2016
    Date of Patent: January 12, 2021
    Assignee: Regents of the University of Minnesota
    Inventor: Michael Olin